Alector, Inc. (ALEC) Hits Record High

Alector, Inc. (NASDAQ:ALEC) reached all time high on Apr, 9 with $27.16 target or 5.00 % above the last $25.87 share price. Barchart.com announced the all time high. The company has $1.78B market cap. At $27.16 target, the company’s valuation could be $89.10 million more.

ALEC is touching $25.87 during the last trading session, after increased 0.39%.Alector, Inc. has volume of 304,837 shares. Since April 9, 2018 ALEC has 0.00% and is . ALEC underperformed by 4.37% the S&P 500.

Alector, Inc. (NASDAQ:ALEC) Ratings Coverage

In total 2 analysts cover Alector (NASDAQ:ALEC). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. 100% are bullish. With $27 highest and $27 lowest target price Alector has $27 average target price or 4.37% above the current ($25.87) price. 4 are the (NASDAQ:ALEC)’s analyst reports since March 4, 2019 according to StockzIntelligence Inc.

For more Alector, Inc. (NASDAQ:ALEC) news released recently go to: Nasdaq.com, Streetinsider.com, Nasdaq.com, Nasdaq.com or Nasdaq.com. The titles are as follows: “U.S. to wrap case against drug company executives tied to opioid crisis – Nasdaq” released on April 04, 2019, “Alector Inc. (ALEC), with Collaboration Partner AbbVie (ABBV), Begin Phase 1 Trial of AL003 for Treatment of Patients with Alzheimer’s Disease – StreetInsider.com” on April 02, 2019, “Crackdown on banks gives Hong Kong an IPO edge – Nasdaq” with a publish date: March 15, 2019, “Japan Post’s insurer returns with better packaging – Nasdaq” and the last “Alector (ALEC) Initiates Phase I Alzheimer’s Study on AL003 – Nasdaq” with publication date: April 03, 2019.

Alector, Inc., a clinical stage biotechnology company, focuses on developing therapies that harness the immune system to cure neurodegenerative diseases.The company has $1.78 billion market cap. The Company’s products in Phase I clinical trial include AL001, a humanized recombinant monoclonal antibody for the treatment of frontotemporal dementia; and AL002 for the treatment of Alzheimer's disease.Last it reported negative earnings. The company's preclinical stage products comprise AL101 for the treatment of Alzheimer's and Parkinson's diseases; and AL003 for the treatment of Alzheimer's disease.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.